This review highlights advances in novel drug-delivery systems, indicating potential improvements in therapeutic outcomes across various conditions.
The continuous evolution of the pharmaceutical sciences has led to significant advancements in the design and development of novel drug-delivery systems (NDDS) to improve therapeutic efficacy, patient compliance, and safety profiles. Conventional dosage forms often exhibit limitations such as poor bioavailability, rapid systemic clearance, and nonspecific distribution. To address these challenges, formulation scientists have integrated nanotechnology, polymer science, lipid-based carriers, and targeted delivery strategies into modern pharmaceutical development. Emerging platforms such as liposomes, solid lipid nanoparticles, nanostructured lipid carriers, polymeric micelles, hydrogels, and stimuli-responsive systems have transformed the delivery and release behavior of active pharmaceutical ingredients. This review consolidates recent advances in NDDS, highlighting formulation approaches, characterization techniques, regulatory considerations, and translational challenges. Emphasis is placed on the clinical potential of these systems in enhancing therapeutic outcomes across diverse disease conditions.
No takes yet. Share an insight, caveat, or question.
Donthula et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: